NASDAQ · APRE
Aprea Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for APRE: Nov 11, 2026
Aprea Therapeutics, Inc. Common stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.08. The reported EPS for the same quarter last year was $-0.47.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.08 | $-0.07 | $-0.09 | 2 |
| Dec 2026 | $-0.09 | $-0.08 | $-0.10 | 2 |
| Mar 2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Jun 2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel- RTTNews · Aug 28, 11:55 AM EDTAprea Expands Patent Portfolio For Precision Oncology Programs(RTTNews) – Aprea Therapeutics, Inc. (APRE), a clinical-stage precision medicine oncology company focused on targeted therapies for biomarker-defined cancers, announced an expansion of its global intellectual property portfolio covering its WEE1 and ATR inhibitor programs.
- RTTNews · Aug 12, 1:15 PM EDTAprea Advances APR-1051; Phase 1 Enrollment Accelerates(RTTNews) – Aprea Therapeutics, Inc. (APRE), a clinical-stage precision medicine oncology company developing targeted therapies for biomarker-defined cancers, reported second-quarter 2026 financial results and provided business updates, highlighting accelerating enrollment in the
- Zacks · Aug 6, 7:10 PM EDTZymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue EstimatesZymeworks (ZYME) delivered earnings and revenue surprises of -10.71% and +25.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 4, 8:25 AM EDTRhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue EstimatesRhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +9.88% and +6.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 21, 12:00 PM EDTAprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should KnowAprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Fintel · May 7, 8:04 PM EDTOppenheimer Initiates Coverage of Aprea Therapeutics (APRE) with Outperform RecommendationFintel reports that on May 7, 2026, Oppenheimer initiated coverage of Aprea Therapeutics (NasdaqCM:APRE) with a Outperform recommendation. Analyst Price Forecast Suggests 438.45% Upside
- RTTNews · Apr 2, 4:12 AM EDTAprea Therapeutics Closes Oversubscribed $30 Mln Private Placement; Stock Down(RTTNews) – Aprea Therapeutics, Inc. (APRE), a clinical-stage precision medicine oncology company, on Wednesday announced the closing of its previously announced oversubscribed $30 million private placement financing on March 31, 2026.
- RTTNews · Mar 31, 11:07 AM EDTWedbush Reaffirms Aprea Therapeutics At Outperform With $7 Price Target(RTTNews) – Wedbush on Tuesday reiterated its Outperform rating and 12-month price Target of $7 for Aprea Therapeutics, Inc. (APRE), a clinical-stage biopharmaceutical company. The company's lead product candidates are APR-1051, in a Phase 1 clinical trial for the treatment of
- RTTNews · Mar 30, 9:18 AM EDTAprea Reports Confirmed Partial Response In APR-1051 Trial And Announced $30M Private Placement(RTTNews) – Aprea Therapeutics, Inc. (APRE) highlighted emerging clinical activity for its WEE1 inhibitor APR-1051, including a confirmed partial response in its ongoing Phase 1 ACESOT-1051 trial, while also securing an oversubscribed $30 million private placement to support cont
- RTTNews · Feb 18, 9:27 AM ESTAprea Reports Additional Positive Clinical Activity For WEE1 Inhibitor APR-1051; Stock Up(RTTNews) – Aprea Therapeutics, Inc. (APRE) announced new preliminary clinical activity from its ongoing Phase 1 ACESOT-1051 trial of APR-1051, including a second unconfirmed partial response in a patient with advanced endometrial cancer.
- RTTNews · Feb 13, 8:24 AM ESTAprea Expands Global Patent Protection To Strengthen Its DDR Oncology Pipeline(RTTNews) – Aprea Therapeutics, Inc. (APRE) has broadened its global intellectual property estate with newly granted patents in Australia and Japan, reinforcing long-term protection for its WEE1 and ATR inhibitor programs and supporting the company's strategy in DNA damage (DDR)
- RTTNews · Jan 30, 12:37 PM ESTWeekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE(RTTNews) – This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic areas such as Endometrial cancer, Colorectal cancer, Weight Management, Acne, and Duchenne muscular
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Aprea Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.